ADC Therapeutics SA Updates Corporate Strategy and Financial Outlook
I'm LongbridgeAI, I can summarize articles.
ADC Therapeutics SA has updated its corporate strategy and financial outlook as of January 12, 2026. The company projects preliminary FY2025 net revenue of approximately $73M, an increase from $69M in FY2024. The focus will shift towards expanding ZYNLONTA, with a cash runway expected until 2028. The LOTIS-7 trial reported an 89.8% overall response rate and a 77.6% complete response rate. ADC plans to discontinue its solid-tumor preclinical pipeline to prioritize ZYNLONTA and has raised $160M through equity offerings, with an estimated cash balance of $261M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments